Global Gaucher Disease Treatment Market

Gaucher Disease Treatment Comprehensive Study by Therapy (Enzyme Replacement Therapy (Imiglucerase (Cerezyme), Velaglucerase alfa (VPRIV),Taliglucerase alfa (Elelyso), Others, Substrate Replacement Therapy (Miglustat, Eliglustat)), Disease Type (Type I (Neuropathic forms), Type II (Perinatal Lethal Form), Type III (Slow-neurologic decay form)), Surgical (Bone Marrow Transplant, Spleen Removal), Distribution Channel (Hospitals, Retail Pharmacies, Online Pharmacies) Players and Region - Global Market Outlook to 2030

Gaucher Disease Treatment Market by XX Submarkets | Forecast Years 2024-2030 | CAGR: 0.79%  

Access Sample Report Make An Enquiry Before Purchase
  • Summary
  • Market Segments
  • Table of Content
  • List of Table & Figures
  • Players Profiled
Gaucher Disease Treatment Market Scope
Gaucher disease is a rare autosomal recessive metabolic disorder, with a prevalence rate of 1 in 100,000 individuals. It is the most common lysosomal storage disorder with Genetic conditions which are caused by mutations in the GBA (Glycosylceramidase Beta) Gene. This mutation leads to reduced production of glucocerebrosidase and a consequent accumulation of glucocerebroside. The Excess lipid accumulates in the brain, Bone marrow, Lungs, Kidney, Liver, and Spleen, which obstructs normal body functions. High dose is prescribed to them for the disease once a week, but, in some cases, a medium dose of medicine is given every week or three times in low dose quantity. However, the increasing prevalence of this disease in all age men & women and the subsequent increase in the number of drugs available in the market is anticipated to propel the market growth.

AttributesDetails
Study Period2018-2030
Base Year2023
Largest MarketNorth America
UnitValue (USD Million)
Key Companies ProfiledGenzyme Corporation (United States), Shire (United States), Pfizer Inc. (United States), Johnson & Johnson Services, Inc.(United States), GlaxoSmithKline (GSK) PLC (United Kingdom), Eli Lilly and Company (United States), Alexion Pharmaceuticals Inc. (United States) and Anthera Pharmaceuticals, Inc. (United States)
CAGR0.79%


The market is a very fragmented market with very few players who rare strictly working for the development of the latest drug therapy. Most of the top players in the Gaucher disease drugs market are located in either Europe or North America. Research Analyst at AMA estimates that United States Players will contribute to the maximum growth of Global Gaucher Disease Treatment market throughout the predicted period.

Genzyme Corporation (United States), Shire (United States), Pfizer Inc. (United States), Johnson & Johnson Services, Inc.(United States), GlaxoSmithKline (GSK) PLC (United Kingdom), Eli Lilly and Company (United States), Alexion Pharmaceuticals Inc. (United States) and Anthera Pharmaceuticals, Inc. (United States) are some of the key players that are part of study coverage. Additionally, the Players which are also part of the research are Lixte Biotechnology Holdings Inc.(United States), JCR Pharmaceuticals Co Ltd.(Japan), Pharming Group NV (Netherlands) and Orphazyme ApS (Denmark).

About Approach
The research aims to propose a patent-based approach in searching for potential technology partners as a supporting tool for enabling open innovation. The study also proposes a systematic searching process of technology partners as a preliminary step to select the emerging and key players that are involved in implementing market estimations. While patent analysis is employed to overcome the aforementioned data- and process-related limitations, as expenses occurred in that technology allows us to estimate the market size by evolving segments as target market from the total available market.

Segmentation Overview
The study have segmented the market of Global Gaucher Disease Treatment market by Type and Region with country level break-up.

On the basis of geography, the market of Gaucher Disease Treatment has been segmented into South America (Brazil, Argentina, Rest of South America), Asia Pacific (China, Japan, India, South Korea, Taiwan, Australia, Rest of Asia-Pacific), Europe (Germany, France, Italy, United Kingdom, Netherlands, Rest of Europe), MEA (Middle East, Africa), North America (United States, Canada, Mexico). North America region held largest market share in the year 2023. Europe on the other hand stood as second largest market due to the presence of key companies into the region and high technological advancement.

Market Leaders and their expansionary development strategies
In 2021, Shire plc and Takeda Pharmaceutical Company Limited announced their merger, creating a company with a leading position in rare disease treatments, including Gaucher Disease.
In 2019, Pfizer received approval from the European Commission for ELELYSO (cerliponase alfa) for the treatment of Type 1 Gaucher Disease in adult and pediatric patients.
In July 2017, The European Medicines Agency (EMA) and the United States Food and Drug Administration (FDA) collaborated to promote the use of innovative approaches in the development of medicines for Gaucher disease.

Influencing Trend:
Type I and type III being treatable by Enzyme Replacement Therapy (ERT) and ERT is seen Effective in Improving the Quality of Life of Patients

Market Growth Drivers:
Strategic Collaboration of Regulatory Bodies for the Development of Novel Innovative Drugs, Rising Demand for Substantial Treatment of the Disease and Increasing Number of People with Brain Disorder

Challenges:
Lack of Awareness Regarding the Symptoms, Diagnosis, and Treatment among Rural Population

Restraints:
Heavily Expensive and Lifelong undertaking Treatment and Limited Clinical Trial Data due to Fewer Patients Getting Affected

Opportunities:
Growing Medical Advancement in Research and Development for Rare Disorders

Key Target Audience
Gaucher Disease Treatment Manufacturers, Government and Regulatory Bodies, Healthcare Facilities, Pharmaceutical Companies, Potential Investors, Downstream Vendors and Traders/Suppliers/Distributors of Gaucher Disease Drugs

Report Objectives / Segmentation Covered

By Therapy
  • Enzyme Replacement Therapy (Imiglucerase (Cerezyme), Velaglucerase alfa (VPRIV),Taliglucerase alfa (Elelyso), Others
  • Substrate Replacement Therapy (Miglustat, Eliglustat)

By Disease Type
  • Type I (Neuropathic forms)
  • Type II (Perinatal Lethal Form)
  • Type III (Slow-neurologic decay form)

By Surgical
  • Bone Marrow Transplant
  • Spleen Removal

By Distribution Channel
  • Hospitals
  • Retail Pharmacies
  • Online Pharmacies

By Regions
  • South America
    • Brazil
    • Argentina
    • Rest of South America
  • Asia Pacific
    • China
    • Japan
    • India
    • South Korea
    • Taiwan
    • Australia
    • Rest of Asia-Pacific
  • Europe
    • Germany
    • France
    • Italy
    • United Kingdom
    • Netherlands
    • Rest of Europe
  • MEA
    • Middle East
    • Africa
  • North America
    • United States
    • Canada
    • Mexico
  • 1. Market Overview
    • 1.1. Introduction
    • 1.2. Scope/Objective of the Study
      • 1.2.1. Research Objective
  • 2. Executive Summary
    • 2.1. Introduction
  • 3. Market Dynamics
    • 3.1. Introduction
    • 3.2. Market Drivers
      • 3.2.1. Strategic Collaboration of Regulatory Bodies for the Development of Novel Innovative Drugs
      • 3.2.2. Rising Demand for Substantial Treatment of the Disease
      • 3.2.3. Increasing Number of People with Brain Disorder
    • 3.3. Market Challenges
      • 3.3.1. Lack of Awareness Regarding the Symptoms, Diagnosis, and Treatment among Rural Population
    • 3.4. Market Trends
      • 3.4.1. Type I and type III being treatable by Enzyme Replacement Therapy (ERT)
      • 3.4.2. ERT is seen Effective in Improving the Quality of Life of Patients
  • 4. Market Factor Analysis
    • 4.1. Porters Five Forces
    • 4.2. Supply/Value Chain
    • 4.3. PESTEL analysis
    • 4.4. Market Entropy
    • 4.5. Patent/Trademark Analysis
  • 5. Global Gaucher Disease Treatment, by Therapy, Disease Type, Surgical, Distribution Channel and Region (value) (2018-2023)
    • 5.1. Introduction
    • 5.2. Global Gaucher Disease Treatment (Value)
      • 5.2.1. Global Gaucher Disease Treatment by: Therapy (Value)
        • 5.2.1.1. Enzyme Replacement Therapy (Imiglucerase (Cerezyme), Velaglucerase alfa (VPRIV),Taliglucerase alfa (Elelyso), Others
        • 5.2.1.2. Substrate Replacement Therapy (Miglustat, Eliglustat)
      • 5.2.2. Global Gaucher Disease Treatment by: Disease Type (Value)
        • 5.2.2.1. Type I (Neuropathic forms)
        • 5.2.2.2. Type II (Perinatal Lethal Form)
        • 5.2.2.3. Type III (Slow-neurologic decay form)
      • 5.2.3. Global Gaucher Disease Treatment by: Surgical (Value)
        • 5.2.3.1. Bone Marrow Transplant
        • 5.2.3.2. Spleen Removal
      • 5.2.4. Global Gaucher Disease Treatment by: Distribution Channel (Value)
        • 5.2.4.1. Hospitals
        • 5.2.4.2. Retail Pharmacies
        • 5.2.4.3. Online Pharmacies
      • 5.2.5. Global Gaucher Disease Treatment Region
        • 5.2.5.1. South America
          • 5.2.5.1.1. Brazil
          • 5.2.5.1.2. Argentina
          • 5.2.5.1.3. Rest of South America
        • 5.2.5.2. Asia Pacific
          • 5.2.5.2.1. China
          • 5.2.5.2.2. Japan
          • 5.2.5.2.3. India
          • 5.2.5.2.4. South Korea
          • 5.2.5.2.5. Taiwan
          • 5.2.5.2.6. Australia
          • 5.2.5.2.7. Rest of Asia-Pacific
        • 5.2.5.3. Europe
          • 5.2.5.3.1. Germany
          • 5.2.5.3.2. France
          • 5.2.5.3.3. Italy
          • 5.2.5.3.4. United Kingdom
          • 5.2.5.3.5. Netherlands
          • 5.2.5.3.6. Rest of Europe
        • 5.2.5.4. MEA
          • 5.2.5.4.1. Middle East
          • 5.2.5.4.2. Africa
        • 5.2.5.5. North America
          • 5.2.5.5.1. United States
          • 5.2.5.5.2. Canada
          • 5.2.5.5.3. Mexico
  • 6. Gaucher Disease Treatment: Manufacturers/Players Analysis
    • 6.1. Competitive Landscape
      • 6.1.1. Market Share Analysis
        • 6.1.1.1. Top 3
        • 6.1.1.2. Top 5
    • 6.2. Peer Group Analysis (2023)
    • 6.3. BCG Matrix
    • 6.4. Company Profile
      • 6.4.1. Genzyme Corporation (United States)
        • 6.4.1.1. Business Overview
        • 6.4.1.2. Products/Services Offerings
        • 6.4.1.3. Financial Analysis
        • 6.4.1.4. SWOT Analysis
      • 6.4.2. Shire (United States)
        • 6.4.2.1. Business Overview
        • 6.4.2.2. Products/Services Offerings
        • 6.4.2.3. Financial Analysis
        • 6.4.2.4. SWOT Analysis
      • 6.4.3. Pfizer Inc. (United States)
        • 6.4.3.1. Business Overview
        • 6.4.3.2. Products/Services Offerings
        • 6.4.3.3. Financial Analysis
        • 6.4.3.4. SWOT Analysis
      • 6.4.4. Johnson & Johnson Services, Inc.(United States)
        • 6.4.4.1. Business Overview
        • 6.4.4.2. Products/Services Offerings
        • 6.4.4.3. Financial Analysis
        • 6.4.4.4. SWOT Analysis
      • 6.4.5. GlaxoSmithKline (GSK) PLC (United Kingdom)
        • 6.4.5.1. Business Overview
        • 6.4.5.2. Products/Services Offerings
        • 6.4.5.3. Financial Analysis
        • 6.4.5.4. SWOT Analysis
      • 6.4.6. Eli Lilly and Company (United States)
        • 6.4.6.1. Business Overview
        • 6.4.6.2. Products/Services Offerings
        • 6.4.6.3. Financial Analysis
        • 6.4.6.4. SWOT Analysis
      • 6.4.7. Alexion Pharmaceuticals Inc. (United States)
        • 6.4.7.1. Business Overview
        • 6.4.7.2. Products/Services Offerings
        • 6.4.7.3. Financial Analysis
        • 6.4.7.4. SWOT Analysis
      • 6.4.8. Anthera Pharmaceuticals, Inc. (United States)
        • 6.4.8.1. Business Overview
        • 6.4.8.2. Products/Services Offerings
        • 6.4.8.3. Financial Analysis
        • 6.4.8.4. SWOT Analysis
  • 7. Global Gaucher Disease Treatment Sale, by Therapy, Disease Type, Surgical, Distribution Channel and Region (value) (2025-2030)
    • 7.1. Introduction
    • 7.2. Global Gaucher Disease Treatment (Value)
      • 7.2.1. Global Gaucher Disease Treatment by: Therapy (Value)
        • 7.2.1.1. Enzyme Replacement Therapy (Imiglucerase (Cerezyme), Velaglucerase alfa (VPRIV),Taliglucerase alfa (Elelyso), Others
        • 7.2.1.2. Substrate Replacement Therapy (Miglustat, Eliglustat)
      • 7.2.2. Global Gaucher Disease Treatment by: Disease Type (Value)
        • 7.2.2.1. Type I (Neuropathic forms)
        • 7.2.2.2. Type II (Perinatal Lethal Form)
        • 7.2.2.3. Type III (Slow-neurologic decay form)
      • 7.2.3. Global Gaucher Disease Treatment by: Surgical (Value)
        • 7.2.3.1. Bone Marrow Transplant
        • 7.2.3.2. Spleen Removal
      • 7.2.4. Global Gaucher Disease Treatment by: Distribution Channel (Value)
        • 7.2.4.1. Hospitals
        • 7.2.4.2. Retail Pharmacies
        • 7.2.4.3. Online Pharmacies
      • 7.2.5. Global Gaucher Disease Treatment Region
        • 7.2.5.1. South America
          • 7.2.5.1.1. Brazil
          • 7.2.5.1.2. Argentina
          • 7.2.5.1.3. Rest of South America
        • 7.2.5.2. Asia Pacific
          • 7.2.5.2.1. China
          • 7.2.5.2.2. Japan
          • 7.2.5.2.3. India
          • 7.2.5.2.4. South Korea
          • 7.2.5.2.5. Taiwan
          • 7.2.5.2.6. Australia
          • 7.2.5.2.7. Rest of Asia-Pacific
        • 7.2.5.3. Europe
          • 7.2.5.3.1. Germany
          • 7.2.5.3.2. France
          • 7.2.5.3.3. Italy
          • 7.2.5.3.4. United Kingdom
          • 7.2.5.3.5. Netherlands
          • 7.2.5.3.6. Rest of Europe
        • 7.2.5.4. MEA
          • 7.2.5.4.1. Middle East
          • 7.2.5.4.2. Africa
        • 7.2.5.5. North America
          • 7.2.5.5.1. United States
          • 7.2.5.5.2. Canada
          • 7.2.5.5.3. Mexico
  • 8. Appendix
    • 8.1. Acronyms
  • 9. Methodology and Data Source
    • 9.1. Methodology/Research Approach
      • 9.1.1. Research Programs/Design
      • 9.1.2. Market Size Estimation
      • 9.1.3. Market Breakdown and Data Triangulation
    • 9.2. Data Source
      • 9.2.1. Secondary Sources
      • 9.2.2. Primary Sources
    • 9.3. Disclaimer
List of Tables
  • Table 1. Gaucher Disease Treatment: by Therapy(USD Million)
  • Table 2. Gaucher Disease Treatment Enzyme Replacement Therapy (Imiglucerase (Cerezyme), Velaglucerase alfa (VPRIV),Taliglucerase alfa (Elelyso), Others , by Region USD Million (2018-2023)
  • Table 3. Gaucher Disease Treatment Substrate Replacement Therapy (Miglustat, Eliglustat) , by Region USD Million (2018-2023)
  • Table 4. Gaucher Disease Treatment: by Disease Type(USD Million)
  • Table 5. Gaucher Disease Treatment Type I (Neuropathic forms) , by Region USD Million (2018-2023)
  • Table 6. Gaucher Disease Treatment Type II (Perinatal Lethal Form) , by Region USD Million (2018-2023)
  • Table 7. Gaucher Disease Treatment Type III (Slow-neurologic decay form) , by Region USD Million (2018-2023)
  • Table 8. Gaucher Disease Treatment: by Surgical(USD Million)
  • Table 9. Gaucher Disease Treatment Bone Marrow Transplant , by Region USD Million (2018-2023)
  • Table 10. Gaucher Disease Treatment Spleen Removal , by Region USD Million (2018-2023)
  • Table 11. Gaucher Disease Treatment: by Distribution Channel(USD Million)
  • Table 12. Gaucher Disease Treatment Hospitals , by Region USD Million (2018-2023)
  • Table 13. Gaucher Disease Treatment Retail Pharmacies , by Region USD Million (2018-2023)
  • Table 14. Gaucher Disease Treatment Online Pharmacies , by Region USD Million (2018-2023)
  • Table 15. South America Gaucher Disease Treatment, by Country USD Million (2018-2023)
  • Table 16. South America Gaucher Disease Treatment, by Therapy USD Million (2018-2023)
  • Table 17. South America Gaucher Disease Treatment, by Disease Type USD Million (2018-2023)
  • Table 18. South America Gaucher Disease Treatment, by Surgical USD Million (2018-2023)
  • Table 19. South America Gaucher Disease Treatment, by Distribution Channel USD Million (2018-2023)
  • Table 20. Brazil Gaucher Disease Treatment, by Therapy USD Million (2018-2023)
  • Table 21. Brazil Gaucher Disease Treatment, by Disease Type USD Million (2018-2023)
  • Table 22. Brazil Gaucher Disease Treatment, by Surgical USD Million (2018-2023)
  • Table 23. Brazil Gaucher Disease Treatment, by Distribution Channel USD Million (2018-2023)
  • Table 24. Argentina Gaucher Disease Treatment, by Therapy USD Million (2018-2023)
  • Table 25. Argentina Gaucher Disease Treatment, by Disease Type USD Million (2018-2023)
  • Table 26. Argentina Gaucher Disease Treatment, by Surgical USD Million (2018-2023)
  • Table 27. Argentina Gaucher Disease Treatment, by Distribution Channel USD Million (2018-2023)
  • Table 28. Rest of South America Gaucher Disease Treatment, by Therapy USD Million (2018-2023)
  • Table 29. Rest of South America Gaucher Disease Treatment, by Disease Type USD Million (2018-2023)
  • Table 30. Rest of South America Gaucher Disease Treatment, by Surgical USD Million (2018-2023)
  • Table 31. Rest of South America Gaucher Disease Treatment, by Distribution Channel USD Million (2018-2023)
  • Table 32. Asia Pacific Gaucher Disease Treatment, by Country USD Million (2018-2023)
  • Table 33. Asia Pacific Gaucher Disease Treatment, by Therapy USD Million (2018-2023)
  • Table 34. Asia Pacific Gaucher Disease Treatment, by Disease Type USD Million (2018-2023)
  • Table 35. Asia Pacific Gaucher Disease Treatment, by Surgical USD Million (2018-2023)
  • Table 36. Asia Pacific Gaucher Disease Treatment, by Distribution Channel USD Million (2018-2023)
  • Table 37. China Gaucher Disease Treatment, by Therapy USD Million (2018-2023)
  • Table 38. China Gaucher Disease Treatment, by Disease Type USD Million (2018-2023)
  • Table 39. China Gaucher Disease Treatment, by Surgical USD Million (2018-2023)
  • Table 40. China Gaucher Disease Treatment, by Distribution Channel USD Million (2018-2023)
  • Table 41. Japan Gaucher Disease Treatment, by Therapy USD Million (2018-2023)
  • Table 42. Japan Gaucher Disease Treatment, by Disease Type USD Million (2018-2023)
  • Table 43. Japan Gaucher Disease Treatment, by Surgical USD Million (2018-2023)
  • Table 44. Japan Gaucher Disease Treatment, by Distribution Channel USD Million (2018-2023)
  • Table 45. India Gaucher Disease Treatment, by Therapy USD Million (2018-2023)
  • Table 46. India Gaucher Disease Treatment, by Disease Type USD Million (2018-2023)
  • Table 47. India Gaucher Disease Treatment, by Surgical USD Million (2018-2023)
  • Table 48. India Gaucher Disease Treatment, by Distribution Channel USD Million (2018-2023)
  • Table 49. South Korea Gaucher Disease Treatment, by Therapy USD Million (2018-2023)
  • Table 50. South Korea Gaucher Disease Treatment, by Disease Type USD Million (2018-2023)
  • Table 51. South Korea Gaucher Disease Treatment, by Surgical USD Million (2018-2023)
  • Table 52. South Korea Gaucher Disease Treatment, by Distribution Channel USD Million (2018-2023)
  • Table 53. Taiwan Gaucher Disease Treatment, by Therapy USD Million (2018-2023)
  • Table 54. Taiwan Gaucher Disease Treatment, by Disease Type USD Million (2018-2023)
  • Table 55. Taiwan Gaucher Disease Treatment, by Surgical USD Million (2018-2023)
  • Table 56. Taiwan Gaucher Disease Treatment, by Distribution Channel USD Million (2018-2023)
  • Table 57. Australia Gaucher Disease Treatment, by Therapy USD Million (2018-2023)
  • Table 58. Australia Gaucher Disease Treatment, by Disease Type USD Million (2018-2023)
  • Table 59. Australia Gaucher Disease Treatment, by Surgical USD Million (2018-2023)
  • Table 60. Australia Gaucher Disease Treatment, by Distribution Channel USD Million (2018-2023)
  • Table 61. Rest of Asia-Pacific Gaucher Disease Treatment, by Therapy USD Million (2018-2023)
  • Table 62. Rest of Asia-Pacific Gaucher Disease Treatment, by Disease Type USD Million (2018-2023)
  • Table 63. Rest of Asia-Pacific Gaucher Disease Treatment, by Surgical USD Million (2018-2023)
  • Table 64. Rest of Asia-Pacific Gaucher Disease Treatment, by Distribution Channel USD Million (2018-2023)
  • Table 65. Europe Gaucher Disease Treatment, by Country USD Million (2018-2023)
  • Table 66. Europe Gaucher Disease Treatment, by Therapy USD Million (2018-2023)
  • Table 67. Europe Gaucher Disease Treatment, by Disease Type USD Million (2018-2023)
  • Table 68. Europe Gaucher Disease Treatment, by Surgical USD Million (2018-2023)
  • Table 69. Europe Gaucher Disease Treatment, by Distribution Channel USD Million (2018-2023)
  • Table 70. Germany Gaucher Disease Treatment, by Therapy USD Million (2018-2023)
  • Table 71. Germany Gaucher Disease Treatment, by Disease Type USD Million (2018-2023)
  • Table 72. Germany Gaucher Disease Treatment, by Surgical USD Million (2018-2023)
  • Table 73. Germany Gaucher Disease Treatment, by Distribution Channel USD Million (2018-2023)
  • Table 74. France Gaucher Disease Treatment, by Therapy USD Million (2018-2023)
  • Table 75. France Gaucher Disease Treatment, by Disease Type USD Million (2018-2023)
  • Table 76. France Gaucher Disease Treatment, by Surgical USD Million (2018-2023)
  • Table 77. France Gaucher Disease Treatment, by Distribution Channel USD Million (2018-2023)
  • Table 78. Italy Gaucher Disease Treatment, by Therapy USD Million (2018-2023)
  • Table 79. Italy Gaucher Disease Treatment, by Disease Type USD Million (2018-2023)
  • Table 80. Italy Gaucher Disease Treatment, by Surgical USD Million (2018-2023)
  • Table 81. Italy Gaucher Disease Treatment, by Distribution Channel USD Million (2018-2023)
  • Table 82. United Kingdom Gaucher Disease Treatment, by Therapy USD Million (2018-2023)
  • Table 83. United Kingdom Gaucher Disease Treatment, by Disease Type USD Million (2018-2023)
  • Table 84. United Kingdom Gaucher Disease Treatment, by Surgical USD Million (2018-2023)
  • Table 85. United Kingdom Gaucher Disease Treatment, by Distribution Channel USD Million (2018-2023)
  • Table 86. Netherlands Gaucher Disease Treatment, by Therapy USD Million (2018-2023)
  • Table 87. Netherlands Gaucher Disease Treatment, by Disease Type USD Million (2018-2023)
  • Table 88. Netherlands Gaucher Disease Treatment, by Surgical USD Million (2018-2023)
  • Table 89. Netherlands Gaucher Disease Treatment, by Distribution Channel USD Million (2018-2023)
  • Table 90. Rest of Europe Gaucher Disease Treatment, by Therapy USD Million (2018-2023)
  • Table 91. Rest of Europe Gaucher Disease Treatment, by Disease Type USD Million (2018-2023)
  • Table 92. Rest of Europe Gaucher Disease Treatment, by Surgical USD Million (2018-2023)
  • Table 93. Rest of Europe Gaucher Disease Treatment, by Distribution Channel USD Million (2018-2023)
  • Table 94. MEA Gaucher Disease Treatment, by Country USD Million (2018-2023)
  • Table 95. MEA Gaucher Disease Treatment, by Therapy USD Million (2018-2023)
  • Table 96. MEA Gaucher Disease Treatment, by Disease Type USD Million (2018-2023)
  • Table 97. MEA Gaucher Disease Treatment, by Surgical USD Million (2018-2023)
  • Table 98. MEA Gaucher Disease Treatment, by Distribution Channel USD Million (2018-2023)
  • Table 99. Middle East Gaucher Disease Treatment, by Therapy USD Million (2018-2023)
  • Table 100. Middle East Gaucher Disease Treatment, by Disease Type USD Million (2018-2023)
  • Table 101. Middle East Gaucher Disease Treatment, by Surgical USD Million (2018-2023)
  • Table 102. Middle East Gaucher Disease Treatment, by Distribution Channel USD Million (2018-2023)
  • Table 103. Africa Gaucher Disease Treatment, by Therapy USD Million (2018-2023)
  • Table 104. Africa Gaucher Disease Treatment, by Disease Type USD Million (2018-2023)
  • Table 105. Africa Gaucher Disease Treatment, by Surgical USD Million (2018-2023)
  • Table 106. Africa Gaucher Disease Treatment, by Distribution Channel USD Million (2018-2023)
  • Table 107. North America Gaucher Disease Treatment, by Country USD Million (2018-2023)
  • Table 108. North America Gaucher Disease Treatment, by Therapy USD Million (2018-2023)
  • Table 109. North America Gaucher Disease Treatment, by Disease Type USD Million (2018-2023)
  • Table 110. North America Gaucher Disease Treatment, by Surgical USD Million (2018-2023)
  • Table 111. North America Gaucher Disease Treatment, by Distribution Channel USD Million (2018-2023)
  • Table 112. United States Gaucher Disease Treatment, by Therapy USD Million (2018-2023)
  • Table 113. United States Gaucher Disease Treatment, by Disease Type USD Million (2018-2023)
  • Table 114. United States Gaucher Disease Treatment, by Surgical USD Million (2018-2023)
  • Table 115. United States Gaucher Disease Treatment, by Distribution Channel USD Million (2018-2023)
  • Table 116. Canada Gaucher Disease Treatment, by Therapy USD Million (2018-2023)
  • Table 117. Canada Gaucher Disease Treatment, by Disease Type USD Million (2018-2023)
  • Table 118. Canada Gaucher Disease Treatment, by Surgical USD Million (2018-2023)
  • Table 119. Canada Gaucher Disease Treatment, by Distribution Channel USD Million (2018-2023)
  • Table 120. Mexico Gaucher Disease Treatment, by Therapy USD Million (2018-2023)
  • Table 121. Mexico Gaucher Disease Treatment, by Disease Type USD Million (2018-2023)
  • Table 122. Mexico Gaucher Disease Treatment, by Surgical USD Million (2018-2023)
  • Table 123. Mexico Gaucher Disease Treatment, by Distribution Channel USD Million (2018-2023)
  • Table 124. Company Basic Information, Sales Area and Its Competitors
  • Table 125. Company Basic Information, Sales Area and Its Competitors
  • Table 126. Company Basic Information, Sales Area and Its Competitors
  • Table 127. Company Basic Information, Sales Area and Its Competitors
  • Table 128. Company Basic Information, Sales Area and Its Competitors
  • Table 129. Company Basic Information, Sales Area and Its Competitors
  • Table 130. Company Basic Information, Sales Area and Its Competitors
  • Table 131. Company Basic Information, Sales Area and Its Competitors
  • Table 132. Gaucher Disease Treatment: by Therapy(USD Million)
  • Table 133. Gaucher Disease Treatment Enzyme Replacement Therapy (Imiglucerase (Cerezyme), Velaglucerase alfa (VPRIV),Taliglucerase alfa (Elelyso), Others , by Region USD Million (2025-2030)
  • Table 134. Gaucher Disease Treatment Substrate Replacement Therapy (Miglustat, Eliglustat) , by Region USD Million (2025-2030)
  • Table 135. Gaucher Disease Treatment: by Disease Type(USD Million)
  • Table 136. Gaucher Disease Treatment Type I (Neuropathic forms) , by Region USD Million (2025-2030)
  • Table 137. Gaucher Disease Treatment Type II (Perinatal Lethal Form) , by Region USD Million (2025-2030)
  • Table 138. Gaucher Disease Treatment Type III (Slow-neurologic decay form) , by Region USD Million (2025-2030)
  • Table 139. Gaucher Disease Treatment: by Surgical(USD Million)
  • Table 140. Gaucher Disease Treatment Bone Marrow Transplant , by Region USD Million (2025-2030)
  • Table 141. Gaucher Disease Treatment Spleen Removal , by Region USD Million (2025-2030)
  • Table 142. Gaucher Disease Treatment: by Distribution Channel(USD Million)
  • Table 143. Gaucher Disease Treatment Hospitals , by Region USD Million (2025-2030)
  • Table 144. Gaucher Disease Treatment Retail Pharmacies , by Region USD Million (2025-2030)
  • Table 145. Gaucher Disease Treatment Online Pharmacies , by Region USD Million (2025-2030)
  • Table 146. South America Gaucher Disease Treatment, by Country USD Million (2025-2030)
  • Table 147. South America Gaucher Disease Treatment, by Therapy USD Million (2025-2030)
  • Table 148. South America Gaucher Disease Treatment, by Disease Type USD Million (2025-2030)
  • Table 149. South America Gaucher Disease Treatment, by Surgical USD Million (2025-2030)
  • Table 150. South America Gaucher Disease Treatment, by Distribution Channel USD Million (2025-2030)
  • Table 151. Brazil Gaucher Disease Treatment, by Therapy USD Million (2025-2030)
  • Table 152. Brazil Gaucher Disease Treatment, by Disease Type USD Million (2025-2030)
  • Table 153. Brazil Gaucher Disease Treatment, by Surgical USD Million (2025-2030)
  • Table 154. Brazil Gaucher Disease Treatment, by Distribution Channel USD Million (2025-2030)
  • Table 155. Argentina Gaucher Disease Treatment, by Therapy USD Million (2025-2030)
  • Table 156. Argentina Gaucher Disease Treatment, by Disease Type USD Million (2025-2030)
  • Table 157. Argentina Gaucher Disease Treatment, by Surgical USD Million (2025-2030)
  • Table 158. Argentina Gaucher Disease Treatment, by Distribution Channel USD Million (2025-2030)
  • Table 159. Rest of South America Gaucher Disease Treatment, by Therapy USD Million (2025-2030)
  • Table 160. Rest of South America Gaucher Disease Treatment, by Disease Type USD Million (2025-2030)
  • Table 161. Rest of South America Gaucher Disease Treatment, by Surgical USD Million (2025-2030)
  • Table 162. Rest of South America Gaucher Disease Treatment, by Distribution Channel USD Million (2025-2030)
  • Table 163. Asia Pacific Gaucher Disease Treatment, by Country USD Million (2025-2030)
  • Table 164. Asia Pacific Gaucher Disease Treatment, by Therapy USD Million (2025-2030)
  • Table 165. Asia Pacific Gaucher Disease Treatment, by Disease Type USD Million (2025-2030)
  • Table 166. Asia Pacific Gaucher Disease Treatment, by Surgical USD Million (2025-2030)
  • Table 167. Asia Pacific Gaucher Disease Treatment, by Distribution Channel USD Million (2025-2030)
  • Table 168. China Gaucher Disease Treatment, by Therapy USD Million (2025-2030)
  • Table 169. China Gaucher Disease Treatment, by Disease Type USD Million (2025-2030)
  • Table 170. China Gaucher Disease Treatment, by Surgical USD Million (2025-2030)
  • Table 171. China Gaucher Disease Treatment, by Distribution Channel USD Million (2025-2030)
  • Table 172. Japan Gaucher Disease Treatment, by Therapy USD Million (2025-2030)
  • Table 173. Japan Gaucher Disease Treatment, by Disease Type USD Million (2025-2030)
  • Table 174. Japan Gaucher Disease Treatment, by Surgical USD Million (2025-2030)
  • Table 175. Japan Gaucher Disease Treatment, by Distribution Channel USD Million (2025-2030)
  • Table 176. India Gaucher Disease Treatment, by Therapy USD Million (2025-2030)
  • Table 177. India Gaucher Disease Treatment, by Disease Type USD Million (2025-2030)
  • Table 178. India Gaucher Disease Treatment, by Surgical USD Million (2025-2030)
  • Table 179. India Gaucher Disease Treatment, by Distribution Channel USD Million (2025-2030)
  • Table 180. South Korea Gaucher Disease Treatment, by Therapy USD Million (2025-2030)
  • Table 181. South Korea Gaucher Disease Treatment, by Disease Type USD Million (2025-2030)
  • Table 182. South Korea Gaucher Disease Treatment, by Surgical USD Million (2025-2030)
  • Table 183. South Korea Gaucher Disease Treatment, by Distribution Channel USD Million (2025-2030)
  • Table 184. Taiwan Gaucher Disease Treatment, by Therapy USD Million (2025-2030)
  • Table 185. Taiwan Gaucher Disease Treatment, by Disease Type USD Million (2025-2030)
  • Table 186. Taiwan Gaucher Disease Treatment, by Surgical USD Million (2025-2030)
  • Table 187. Taiwan Gaucher Disease Treatment, by Distribution Channel USD Million (2025-2030)
  • Table 188. Australia Gaucher Disease Treatment, by Therapy USD Million (2025-2030)
  • Table 189. Australia Gaucher Disease Treatment, by Disease Type USD Million (2025-2030)
  • Table 190. Australia Gaucher Disease Treatment, by Surgical USD Million (2025-2030)
  • Table 191. Australia Gaucher Disease Treatment, by Distribution Channel USD Million (2025-2030)
  • Table 192. Rest of Asia-Pacific Gaucher Disease Treatment, by Therapy USD Million (2025-2030)
  • Table 193. Rest of Asia-Pacific Gaucher Disease Treatment, by Disease Type USD Million (2025-2030)
  • Table 194. Rest of Asia-Pacific Gaucher Disease Treatment, by Surgical USD Million (2025-2030)
  • Table 195. Rest of Asia-Pacific Gaucher Disease Treatment, by Distribution Channel USD Million (2025-2030)
  • Table 196. Europe Gaucher Disease Treatment, by Country USD Million (2025-2030)
  • Table 197. Europe Gaucher Disease Treatment, by Therapy USD Million (2025-2030)
  • Table 198. Europe Gaucher Disease Treatment, by Disease Type USD Million (2025-2030)
  • Table 199. Europe Gaucher Disease Treatment, by Surgical USD Million (2025-2030)
  • Table 200. Europe Gaucher Disease Treatment, by Distribution Channel USD Million (2025-2030)
  • Table 201. Germany Gaucher Disease Treatment, by Therapy USD Million (2025-2030)
  • Table 202. Germany Gaucher Disease Treatment, by Disease Type USD Million (2025-2030)
  • Table 203. Germany Gaucher Disease Treatment, by Surgical USD Million (2025-2030)
  • Table 204. Germany Gaucher Disease Treatment, by Distribution Channel USD Million (2025-2030)
  • Table 205. France Gaucher Disease Treatment, by Therapy USD Million (2025-2030)
  • Table 206. France Gaucher Disease Treatment, by Disease Type USD Million (2025-2030)
  • Table 207. France Gaucher Disease Treatment, by Surgical USD Million (2025-2030)
  • Table 208. France Gaucher Disease Treatment, by Distribution Channel USD Million (2025-2030)
  • Table 209. Italy Gaucher Disease Treatment, by Therapy USD Million (2025-2030)
  • Table 210. Italy Gaucher Disease Treatment, by Disease Type USD Million (2025-2030)
  • Table 211. Italy Gaucher Disease Treatment, by Surgical USD Million (2025-2030)
  • Table 212. Italy Gaucher Disease Treatment, by Distribution Channel USD Million (2025-2030)
  • Table 213. United Kingdom Gaucher Disease Treatment, by Therapy USD Million (2025-2030)
  • Table 214. United Kingdom Gaucher Disease Treatment, by Disease Type USD Million (2025-2030)
  • Table 215. United Kingdom Gaucher Disease Treatment, by Surgical USD Million (2025-2030)
  • Table 216. United Kingdom Gaucher Disease Treatment, by Distribution Channel USD Million (2025-2030)
  • Table 217. Netherlands Gaucher Disease Treatment, by Therapy USD Million (2025-2030)
  • Table 218. Netherlands Gaucher Disease Treatment, by Disease Type USD Million (2025-2030)
  • Table 219. Netherlands Gaucher Disease Treatment, by Surgical USD Million (2025-2030)
  • Table 220. Netherlands Gaucher Disease Treatment, by Distribution Channel USD Million (2025-2030)
  • Table 221. Rest of Europe Gaucher Disease Treatment, by Therapy USD Million (2025-2030)
  • Table 222. Rest of Europe Gaucher Disease Treatment, by Disease Type USD Million (2025-2030)
  • Table 223. Rest of Europe Gaucher Disease Treatment, by Surgical USD Million (2025-2030)
  • Table 224. Rest of Europe Gaucher Disease Treatment, by Distribution Channel USD Million (2025-2030)
  • Table 225. MEA Gaucher Disease Treatment, by Country USD Million (2025-2030)
  • Table 226. MEA Gaucher Disease Treatment, by Therapy USD Million (2025-2030)
  • Table 227. MEA Gaucher Disease Treatment, by Disease Type USD Million (2025-2030)
  • Table 228. MEA Gaucher Disease Treatment, by Surgical USD Million (2025-2030)
  • Table 229. MEA Gaucher Disease Treatment, by Distribution Channel USD Million (2025-2030)
  • Table 230. Middle East Gaucher Disease Treatment, by Therapy USD Million (2025-2030)
  • Table 231. Middle East Gaucher Disease Treatment, by Disease Type USD Million (2025-2030)
  • Table 232. Middle East Gaucher Disease Treatment, by Surgical USD Million (2025-2030)
  • Table 233. Middle East Gaucher Disease Treatment, by Distribution Channel USD Million (2025-2030)
  • Table 234. Africa Gaucher Disease Treatment, by Therapy USD Million (2025-2030)
  • Table 235. Africa Gaucher Disease Treatment, by Disease Type USD Million (2025-2030)
  • Table 236. Africa Gaucher Disease Treatment, by Surgical USD Million (2025-2030)
  • Table 237. Africa Gaucher Disease Treatment, by Distribution Channel USD Million (2025-2030)
  • Table 238. North America Gaucher Disease Treatment, by Country USD Million (2025-2030)
  • Table 239. North America Gaucher Disease Treatment, by Therapy USD Million (2025-2030)
  • Table 240. North America Gaucher Disease Treatment, by Disease Type USD Million (2025-2030)
  • Table 241. North America Gaucher Disease Treatment, by Surgical USD Million (2025-2030)
  • Table 242. North America Gaucher Disease Treatment, by Distribution Channel USD Million (2025-2030)
  • Table 243. United States Gaucher Disease Treatment, by Therapy USD Million (2025-2030)
  • Table 244. United States Gaucher Disease Treatment, by Disease Type USD Million (2025-2030)
  • Table 245. United States Gaucher Disease Treatment, by Surgical USD Million (2025-2030)
  • Table 246. United States Gaucher Disease Treatment, by Distribution Channel USD Million (2025-2030)
  • Table 247. Canada Gaucher Disease Treatment, by Therapy USD Million (2025-2030)
  • Table 248. Canada Gaucher Disease Treatment, by Disease Type USD Million (2025-2030)
  • Table 249. Canada Gaucher Disease Treatment, by Surgical USD Million (2025-2030)
  • Table 250. Canada Gaucher Disease Treatment, by Distribution Channel USD Million (2025-2030)
  • Table 251. Mexico Gaucher Disease Treatment, by Therapy USD Million (2025-2030)
  • Table 252. Mexico Gaucher Disease Treatment, by Disease Type USD Million (2025-2030)
  • Table 253. Mexico Gaucher Disease Treatment, by Surgical USD Million (2025-2030)
  • Table 254. Mexico Gaucher Disease Treatment, by Distribution Channel USD Million (2025-2030)
  • Table 255. Research Programs/Design for This Report
  • Table 256. Key Data Information from Secondary Sources
  • Table 257. Key Data Information from Primary Sources
List of Figures
  • Figure 1. Porters Five Forces
  • Figure 2. Supply/Value Chain
  • Figure 3. PESTEL analysis
  • Figure 4. Global Gaucher Disease Treatment: by Therapy USD Million (2018-2023)
  • Figure 5. Global Gaucher Disease Treatment: by Disease Type USD Million (2018-2023)
  • Figure 6. Global Gaucher Disease Treatment: by Surgical USD Million (2018-2023)
  • Figure 7. Global Gaucher Disease Treatment: by Distribution Channel USD Million (2018-2023)
  • Figure 8. South America Gaucher Disease Treatment Share (%), by Country
  • Figure 9. Asia Pacific Gaucher Disease Treatment Share (%), by Country
  • Figure 10. Europe Gaucher Disease Treatment Share (%), by Country
  • Figure 11. MEA Gaucher Disease Treatment Share (%), by Country
  • Figure 12. North America Gaucher Disease Treatment Share (%), by Country
  • Figure 13. Global Gaucher Disease Treatment share by Players 2023 (%)
  • Figure 14. Global Gaucher Disease Treatment share by Players (Top 3) 2023(%)
  • Figure 15. Global Gaucher Disease Treatment share by Players (Top 5) 2023(%)
  • Figure 16. BCG Matrix for key Companies
  • Figure 17. Genzyme Corporation (United States) Revenue, Net Income and Gross profit
  • Figure 18. Genzyme Corporation (United States) Revenue: by Geography 2023
  • Figure 19. Shire (United States) Revenue, Net Income and Gross profit
  • Figure 20. Shire (United States) Revenue: by Geography 2023
  • Figure 21. Pfizer Inc. (United States) Revenue, Net Income and Gross profit
  • Figure 22. Pfizer Inc. (United States) Revenue: by Geography 2023
  • Figure 23. Johnson & Johnson Services, Inc.(United States) Revenue, Net Income and Gross profit
  • Figure 24. Johnson & Johnson Services, Inc.(United States) Revenue: by Geography 2023
  • Figure 25. GlaxoSmithKline (GSK) PLC (United Kingdom) Revenue, Net Income and Gross profit
  • Figure 26. GlaxoSmithKline (GSK) PLC (United Kingdom) Revenue: by Geography 2023
  • Figure 27. Eli Lilly and Company (United States) Revenue, Net Income and Gross profit
  • Figure 28. Eli Lilly and Company (United States) Revenue: by Geography 2023
  • Figure 29. Alexion Pharmaceuticals Inc. (United States) Revenue, Net Income and Gross profit
  • Figure 30. Alexion Pharmaceuticals Inc. (United States) Revenue: by Geography 2023
  • Figure 31. Anthera Pharmaceuticals, Inc. (United States) Revenue, Net Income and Gross profit
  • Figure 32. Anthera Pharmaceuticals, Inc. (United States) Revenue: by Geography 2023
  • Figure 33. Global Gaucher Disease Treatment: by Therapy USD Million (2025-2030)
  • Figure 34. Global Gaucher Disease Treatment: by Disease Type USD Million (2025-2030)
  • Figure 35. Global Gaucher Disease Treatment: by Surgical USD Million (2025-2030)
  • Figure 36. Global Gaucher Disease Treatment: by Distribution Channel USD Million (2025-2030)
  • Figure 37. South America Gaucher Disease Treatment Share (%), by Country
  • Figure 38. Asia Pacific Gaucher Disease Treatment Share (%), by Country
  • Figure 39. Europe Gaucher Disease Treatment Share (%), by Country
  • Figure 40. MEA Gaucher Disease Treatment Share (%), by Country
  • Figure 41. North America Gaucher Disease Treatment Share (%), by Country
List of companies from research coverage that are profiled in the study
  • Genzyme Corporation (United States)
  • Shire (United States)
  • Pfizer Inc. (United States)
  • Johnson & Johnson Services, Inc.(United States)
  • GlaxoSmithKline (GSK) PLC (United Kingdom)
  • Eli Lilly and Company (United States)
  • Alexion Pharmaceuticals Inc. (United States)
  • Anthera Pharmaceuticals, Inc. (United States)
Additional players considered in the study are as follows:
Lixte Biotechnology Holdings Inc.(United States) , JCR Pharmaceuticals Co Ltd.(Japan) , Pharming Group NV (Netherlands) , Orphazyme ApS (Denmark)
Select User Access Type

Key Highlights of Report


Feb 2024 156 Pages 58 Tables Base Year: 2023 Coverage: 15+ Companies; 18 Countries

Request Sample Pages

Budget constraints? Get in touch with us for special pricing


Check Discount Now
Global Gaucher Disease Treatment Market Quantitative research analysis
Global Gaucher Disease Treatment Market Qualitative Industry Analysis
DOWNLOAD SAMPLE PDF

Talk to Our Experts

Want to Customize Study?


"We employ Market statistics, Industry benchmarking, Patent analysis, and Technological Insights to derive requirements and provide customize scope of work."

Make an Enquiry Now

Frequently Asked Questions (FAQ):

The key segments that are playing vital role in Gaucher Disease Treatment Market are by end use application [].
The Gaucher Disease Treatment Market is gaining popularity and expected to see strong valuation by 2030.
  • Strategic Collaboration of Regulatory Bodies for the Development of Novel Innovative Drugs
  • Rising Demand for Substantial Treatment of the Disease
  • Increasing Number of People with Brain Disorder

Know More About Global Gaucher Disease Treatment Market Report?

Have a Query? Click Here

Other Related Reports

Post-Traumatic Stress Disorder Therapeutics Comprehensive Study by End-Users (Male, Female, Children), Drug Class (Antidepressants, Anti-anxiety Drugs, Other Drug Class) Players and Region - Global M...
$ 3500
Thalassemia Comprehensive Study by Type (Alpha-Thalassemia, Beta Thalassemia), Application (Hospital, Clinic, Research Institute, Laboratories), Treatment Type (Blood Transfusions, Iron Chelation The...
$ 3650
Melanoma Therapeutics Comprehensive Study by Drugs (Opdivo, Yervoy, Mekinist+Tafinlar, Keytruda, Cotellic, Zelboraf, Imlygic, Generics), Therapy (Chemotherapy, Immunotherapy, Targeted Therapy, Radiat...
$ 3750
Appendix Cancer Treatment Comprehensive Study by Type (Neuroendocrine Tumors, Carcinomas, Mucinous Adenocarcinoma (low grade, high grade), Global Cell Carcinoids, Intestinal Type Adenocarcinoma, Sign...
$ 3750
Diabetes Therapeutics and Diagnostics Comprehensive Study by Type (Injectable (Insulin, Amylinomimetic), Oral (Biguanides, Sulfonylureas, Thiazolidinediones, Alpha-Glucosidase Inhibitors, Dipeptidyl ...
$ 3750
Daptomycin Comprehensive Study by Type (350 mg lyophilized powder, 500 mg lyophilized powder), Application (Adult, Pediatric patients (1 to 17 years of age)), End -Users (Pharmaceuticals, Clinics, We...
$ 3500